Results 201 to 210 of about 11,680 (228)

Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi‐drug refractory patients: A case series of high efficacy and safety profile

Dermatologic Therapy, 2020
Secukinumab, the first monoclonal antibody that inhibits interleukin‐17A, has been shown to have rapid and long‐lasting efficacy in the treatment of moderate‐to‐severe psoriasis.
A. Polat Ekinci, K. Bölük, G. B. Kobaner   +2 more
semanticscholar   +1 more source

Solid Lipid Nanoparticles as Carrier to Increase Local Bioavailability of Acitretin After Topical Administration in Psoriasis Treatment

Journal of Pharmaceutical Innovation, 2022
M. Mahajan, M. Kaur, Shubham Thakur, Amrinder Singh, Navid Reza Shahtaghi, Riya Shivgotra, N. Bhardwaj, Shagun Saini, S. Jain   +8 more
semanticscholar   +1 more source

Formulation, Evaluation and Optimization of Acitretin Loaded Transethosomes for the Management of Psoriasis

Journal of Pharmaceutical Innovation
Shivaprasad S. Bevinakoppamath, P. Dandagi, Sujay Hulyalkar, P. Biradar   +3 more
semanticscholar   +1 more source

Acitretin

Reactions Weekly, 2015
  +5 more sources

Acitretin

Reactions Weekly
  +5 more sources

ACITRETIN

Reactions Weekly, 2002
openaire   +2 more sources

Acitretin

Reactions Weekly, 2007
openaire   +2 more sources

Acitretin

Reactions Weekly, 2019
  +4 more sources

Acitretin

Reactions Weekly, 2011
openaire   +1 more source

Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IκBζ

International Immunopharmacology, 2020
Zhiqiang Yin
exaly